A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...

England’s drug-cost regulator rejected Eli Lilly’s Alzheimer’s drug for use in the country’s public health system, marking ...

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the ...

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the ...

The drugmaker Eli Lilly told the-then UK health secretary last year that its new Alzheimer’s drug could be a one-off preventive treatment course, despite limited data to back up these claims, freedom ...

Eli Lilly invests £279M in the UK to boost life sciences, while its Alzheimer's drug, donanemab, faces European regulatory ...

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...

350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes ...

Britian's National Institute for Health and Care Excellence said more evidence was needed to prove Kisunla's worth. Lilly ...

UK MHRA grants marketing approval to Lilly's Kisunla to treat mild cognitive impairment and mild dementia due to Alzheimer's disease: Indianapolis Thursday, October 24, 2024, 09:0 ...

The UK's Medicines and Healthcare products Regulatory Agency approved donanemab, manufactured by Eli Lilly (LLY), to slow the progression of Alzheimer's disease.Following this ...